2020-09-30-accounts

Objective	s and	activities
			SORP reference
Summary	ofthe purposes ofthe		Pere 1.17	1.To relieve sickness and to preserve and
charity as	set out	in its		protect health by providing support to chronic
governing	document			lymphocytic leukaemia (CLL) patients and their
				carers. (CLL includes similar related conditions
				such as SLL).
				2.To advance public education in CLL related
				matters primarily in the UK through publications
				and the internet.
				3.To promote and support scientific research
				into the treatment and care of all CLL patients.
Summary in relation	ofthe main activities to those purposes for		Para 1.17and 1.19	1.The provision of up to date and accessible information about CLL, the range oftreatments
the public	benefit,	in particular,		currently available and the latest research into
the activities, projects or				the care and treatment of CLL, through its
services identified		in the		website, member conferences, publications and
accounts.				a telephone helpline.
				2.The development ofopportunities to share
				understanding and personal experience by
				bringing CLL patients together, and by creating
				mutual support groups and networks.
				3.Acting as a voice for CLL patients,
				representing their interests with the
				pharmaceutical industry, clinicians, NHS, cancer
				care policy and drug regulatory authorities,
				funding and commissioning groups and
				Government.
				4.The promotion ofawareness of CLLSA,
				together with its role amongst health care
				providers and decision makers, providers of non-
				healthcare products and services, other blood
				cancer patient groups and the wider public.

	treatment ofCLL, and by key players
	directly involved in the development of
	the preventative vaccines that are seen
	as a way ofeventually establishing some
	form ofcontrol over the Covid-19
	pandemic. The information thus provided
	has proved vital in offering to CLL
	patients and their supporters, clear and
	knowledgeable guidance as to how the
	measures taken will have impacted on
	their particular circumstances.
3.	Continued its work with the Blood Cancer
	Alliance and with Cancer52 to promote
	the interests ofblood cancer generally,
	and CLL in particular
4.	Continued to develop partnering
	arrangements with major pharmaceutical
	companies to offer key insights into the
	way in which treatments impact on the
	lives and wellbeing ofpatients.
The Charity continued to benefit from donations
and fundraising activities that were undertaken
by its supporters despite the limitations that were
placed	on these activities as a result ofthe
restrictions put in place by HM Government to
combat	the pandemic.
The Charity continued to benefit also from
funding	provided by grant making organisations
and by	the pharmaceutical industry.

You ma	choose to include further	statements	where relevant about:
Policies	and procedures	Para 1.51
adopted	for the induction and
training	oftrustees
The charity's organisational		Para 1.51
structure	and any wider network
with which the charity works
Relationship with any related		Para 1.51
parties
Other